Single-Dose Clesrovimab Safely Lowers RSV Infections and Hospitalizations in Infants: NEJM
Researchers have found in a new clinical trial that a single dose of clesrovimab, a long-acting investigational monoclonal antibody targeting site IV of the respiratory syncytial virus (RSV) fusion protein, significantly reduced the risk of RSV-associated illness in healthy infants. The study, published in The New England Journal of Medicine, evaluated the safety and efficacy […]